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Effect of parathyroid hormone on myocardial energy metnholism in the
rat. This study examined the effect of parathyroid hormone (PTH) on
myocardial energy production, transfer, and utilization. Rats (150 to 200
g) were injected with 1-84 PTH, 200 U/day i.p., or 1-34 PTH, 200 or 300
U/day i,p., for 4 days. Control animals received the vehicle only. The
effect of the simultaneous administration of calcium channel blocker,
verapamil, was also examined. Myocardial contents of Pi, ATP, and CP
were significantly (P < 0.01) lower in the 1-84 PTH-treated rats than in
control animals. Both 1-84 PTH and 1-34 significantly (P c 0.01)
reduced mitochondrial oxygen consumption without altering ADP:O
ratio indicating reduced phosphorylation. 1-84 and 1-34 PTH signifi-
cantly (P < 0.01) reduced the activities of mitochondrial and myofibril-
lar creatine phosphokinase and 1-84 PTH inhibited (P C 0.01) the
activities of mitochondrial Mg ATPase and those of myofibrillar Ca
ATPase. There were significant (P C 0.01) increments in myocardial
45Ca and in total calcium content in 1-84 PTH-treated rats. Verapamil
abolished all the effects of 1-84 PTH. Similarly, inactivation of 1-84
PTI-1 abolished its effects. Treatment with 1-84 PTH for 10 days was
associated with a significant decrease in cardiac index and mean arterial
pressure. Our data demonstrate that both 1-84 and 1-34 PTH impair
energy production, transfer, and utilization. These biochemical de-
rangements, if maintained, produce a decrease in cardiac index. It
appears that the enhanced entry and the accumulation of calcium in the
myocardium, either directly and/or indirectly, are responsible for the
action of P'FH on energy metabolism of the heart.
Effet de I'hormone parathyroidienne sur le métabolisme énergétique
myocardique chez le rat. Cette étude a examine l'effet de l'hormone
parathyroidienne (PTH) sur Ia production, le transfert et l'utilisation de
l'energie myocardique. Des rats (150 a 200 g) ont reçu des injections de
PTH 1-84, 200 U/jour i.p., ou de PTH 1-34, 200 ou 300/jour i.p., pendant
4jours. Les animaux contrOles ont reçu le solvant seulement. L'effet de
l'administration simultanee d'un bloqueur des canaux calciques, Ic
vérapamil, a aussi EtC EtudiE. Le contenu myocardique en Pi, ATP, et
CP Etait significativement (P C 0,01) moindre chez les animaux traitEs
par la PTH 1-84 que chez les animaux contrôles. Les PTFI 1-84 et 1-34
ont rEduit chacune significativement (P C 0,01) la consommation
mitochondriale d'oxygene sans altErer le rapport ADP:O, indiquant une
phosphorylation rEduite. Les PTH 1-84 et 1-34 ont significativement (P
<0,01) rEduit les activitCs crEatinine phosphokinases mitochondriale et
myofibrillaire et al PTH 1-84 a inhibe (P C 0,01) les activités Mg ATPase
mitochondriale et Ca ATPase myofibrillaire. 11 existait un accroisse-
ment significatif (P C 0,01) du contenu myocardique en 45CA et en
calcium total chez les rats traités par la PTH 1-84. Le vérapamil a aboli
tous les effets de la PTH 1-84. De mEme, I'inactivation de Ia PTH 1-84
a supprimE ses effets. Le traitement par Ia PTH 1-84 pendant 10 jours
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Etait associE avec une baisse significative de l'index cardiaque et de la
pression artErielle moyenne. Nos donnEcs dCmontrent que les PTH 1-84
altèrent Ia production, le transfert, et l'utilisation d'Cnergie. Que ces
anomalies biochimiques, si elles persistent, produisent une diminution
de l'index cardiaque. II apparait que l'augmentation de l'entrCe et
l'accumulation de calcium dans le myocarde, directement et/ou
indirectement, sont responsables de l'action de la PTH sur le
mEtabolisme énergEtique du coeur.
Reported evidence indicates that parathyroid hormone (PTH)
affects the heart: First, Selye [1] and Lehr [2] found that cardiac
lesions characterized by calcium deposits in the myocardium
and the coronary arteries occur in rats after bilateral nephrec-
tomy or bilateral ureteral ligation; administration of PTH en-
hanced the development of these lesions and parathyroidecto-
my either inhibited or completely prevented their evolution.
Second, Bogin, Massry, and Harary [3] demonstrated that the
heart is a target organ for PTH; the hormone stimulated cyclic
AMP production by heart cells, increased their beating rate and
caused their death after prolonged exposure. Third, Lhoste,
Drueke, and Boissier [4] reported that PTH antagonized the
depressant effect of propranolol on the contractile force of
isolated guinea pig auricles. Fourth, Kahot et al [5] described an
increase in the contractile force of papillary muscle by PTH.
Finally, Drueke et al [6] noticed marked improvement in left
ventricular function after parathyroidectomy in 22 dialysis
patients who exhibited secondary hyperparathyroidism.
The results of our studies [3] and those of Lhoste, Drueke,
and Boissier [4] have shown that the effect of PTH on the heart
is mediated by increased movement of calcium into the heart
cells. However, calcium overload may exert an adverse effect
on the myocardium. Fleckenstein [7] has shown that calcium
overload of the myocardium induced by catecholamines was
associated with a deficiency of high energy phosphate com-
pounds; he found a significant fall in cellular ATP.
The effects of PTH on the bioenergetics of the myocardium
are not known. The understanding of the possible alterations in
these biochemical events may shed light on the mechanisms of
action of the hormone on the heart. The present study examined
the effects of the in vivo administration of PTH on the various
steps of the myocardial bioenergetics including (1) adenine
nucleotides and creatine phosphate contents, (2) mitochondrial
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energy production and transport, and (3) myofibrillar energy
utilization. Also, the effect of the prolonged administration of
the hormone on cardiac output was evaluated.
Methods
Sprague-Dawley rats weighing 150 to 200 g were used in the
study. Because previous studies in our laboratory [31 show that
both the synthetic 1-34 fragment of PTH and the purified bovine
intact hormone molecule (1-84 bPTH) acted on the heart cells,
and because the effect of the latter was greater, we used 1-84
bPTH (Sigma Chemical Co., St. Louis, Missouri, USA) in most
of the experiments of the present study. Preliminary experi-
ments utilizing protocols of 1, 2, and 4 days of PTH administra-
tion demonstrated that a clear-cut effect on myocardial
bioenergetics occurs after 4 days of PTH treatment. Therefore,
the present study utilized the 4-day protocol.
The rats received an intraperitoneal injection of 200 U/day of
1-84 PTH dissolved in normal saline for 4 days while control
animals received sham injections of the vehicle only. The
animals were fed normal rat chow (ICN Nutritional Biochemi-
cal, Cleveland, Ohio, USA) throughout the study. The various
parameters of the myocardial bioenergetics were evaluated on
the morning of day 5. Studies were also carried out utilizing 200
U/day of inactivated 1-84 PTH and 200 U or 300 U/day of active
1-34 PTH (Sigma Chemical Co.) given in divided doses. The
inactivation of 1-84 PTH was carried out as follows: 10 to 15 g
of PTH was dissolved in 60 d 0.15 N acetic acid, and to this
solution 40 l of 30% vol/vol H202 were added. The solution
was incubated at 37°C for 45 mm, and the reaction was
terminated by freezing and lyophilizing. In all animals, blood
samples were obtained for the measurements of the concentra-
tion of calcium with an atomic absorption spectrophotometer
(Model 505, Perkin Elmer Corp., Norwalk, Connecticut, USA)
and of inorganic phosphorus with an autoanalyzer (Technicon
Corp., Tarrytown, New York, USA).
Measurement of adenine nucleotides and creatine phosphate
The rats were anesthetized with an intraperitoneal injection
of 5 mg of pentobarbitallkg of body weight, intubated and
respirated to maintain P02 at 85 to 90 mm Hg and Pco2 at 37 to
42 mm Hg. The chest was opened at the sternum, and we used
freeze-clamping liquid nitrogen techniques [8] to take a biopsy
specimen from the left ventricle. Inorganic phosphorus (Pi),
adenine nucleotides, and creatine phosphate were determined
with the automatic phosphate analyzer of Bessman et al [91 as
described previously from our laboratory [10]. By means of
relative retention times, the peaks obtained in a chromatogram
of the biopsy specimen were compared with those obtained by
using synthetic standards. All peaks of interest were identified
both by internal standards and chromatography with a known
amount of authentic compounds. Recovery for individual
metabolites was evaluated using measurements of known stan-
dard with and without the column. Creatine was measured by
an enzymatic method [11], protein was determined using a
modification of the method described by Lowry et al [121, and
DNA was estimated by the method of Burton [13].
Evaluation of mitochondrial energy production and transport
Mitochondrial energy production was examined using
mitochondria isolated by the method described by Yang, Gei-
ger, and Bessman [14]. The rats were killed by decapitation; the
hearts were removed and washed of blood. The ventricles were
placed in an ice-cold homogenization medium containing 0.3 M
mannitol, 0.1 mM EDTA, and 10 m Tris buffer at pH 7.2.
Tissue samples were then cut into small pieces and run through
a tissue press (Harvard). Since rat myocardium is resistant to
mechanical homogenization, tissue samples were treated for 30
mm with trypsin. At the end of 30 mm, a trypsin inhibitor was
used to stop the reaction. The fine tissue was then homogenized
with a Dounce-type homogenizer. After final homogenization,
the homogenate was centrifuged for 10 mm, at x400g in a
refrigerated centrifuge (International). The pellet was discarded
and the supernatant centrifuged at X 8,000g for 10 mm, for final
isolation of mitochondria. The mitochondrial pellet was washed
several times and then suspended in a medium containing (1)
homogenization medium, (2) 0.5% (wt/vol) dialyzed albumin,
(3) 0.1 M Tris-phosphate buffer, pH 7.2. The protein concentra-
tion of the mitochondrial pellet was determined by a modifica-
tion of the Lowry method [12].
The substrate oxidation rate and ADP/O ratio were deter-
mined polarographically by means of a Clark oxygen electrode
(Gilson Medical Electronics, Middleton, Wisconsin, USA) fit-
ted to a chamber (Plexiglass) of 2.0 ml capacity as described
originally by Chance and Williams [15]. The complete system
contained 1 mg of mitochondrial protein added to 2 ml of
incubation medium containing (in mM): 50 KC1, 10 Tris-HCI
buffer (pH 7.4), 10 to 20 potassium phosphate buffer (pH 7.4), 8
MgCl2, 65 sucrose, 0.2 cytochrome c, 1 NAD, and 0.5 EDTA,
and 0.05% bovine serum albumin. The substrate used in our
incubate was 3.5 m a-ketoglutarate. This methodology is
based on the observation that when tightly coupled
mitochondria are suspended in an isotonic buffer, a slow rate of
oxygen uptake is measured in the presence of substrate and
absence of ADP. The added ADP will cause an immediate
increase in oxygen uptake dependent on the concentration of
ADP added to the reaction. The rate of oxygen uptake is related
directly to the amount of ADP phosphorylated to ATP. The
ADP/O ratio, which is equivalent to the P/O ratio, can be
calculated. Maximal oxygen consumption was achieved by the
addition of ADP in excess (17 mM). Respiratory control ratio is
defined as the rate of state 3 respiration (mitochondria + ADP
+ substrate) divided by the rate of state 4 respiration (mito-
chondrial + substrate + ATP) [15]. To further evaluate the
process of coupling between mitochondrial electron transport
and ATP production, the activity of Mg ATPase was deter-
mined utilizing the method of Mitnacht, Sherman, and Farber
[16]. The activity of mitochondrial magnesium-stimulated
ATPase was determined by measuring the liberation of in-
organic phosphate from 6 m ATP in a 2-ml reaction medium
containing intact mitochondria (2 to 3 mg protein), 74 mM KC1,
50 m sucrose, 50 mM Tris HC1 (pH 7.4), and 1 m'i EDTA. In
all measurements, magnesium was present at the concentration
of 4 m to assess specificity of the reaction.
Since energy transport from the mitochondria occurs via the
creatine phosphate shuttle [17, 18] and is regulated at least
partially by the mitochondrial creatine kinase isoenzyme [18,
19], the effect of PTH on the activity of this enzyme and on its
ability to phosphorylate creatine at stage 4 mitochondrial res-
piration was examined. Assay for mitochondrial creatine kinase
was done with modification of a method described by Oscai and
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Holloszy [201. The activity of creatine kinase was measured
with a system coupled with pyruvate kinase and lactate dehy-
drogenase. The assay mixture contained, in the final volume of
1 ml, 50 moles Tris-HC1, pH 9.0, 5 tmoles ATP, 30 moles
creatine, 2.4 moles phosphoenolpyruvate, 0.15 mo1es
NADH, and 50 mg lactate dehydrogenase. The reaction was
started by adding creatine, and the oxidation of NADH was
followed spectrophotometrically.
Evaluation of energy utilization
Because energy utilization by the contractile myofibrils is
mediated via the myofibrillar creatine kinase isoenzyme and
CA ATPase, the effects of PTH on the activity of these
enzymes were examined. Cardiac myofibrils were isolated and
purified according to the method of Solaro, Pang, and Briggs
[211. The myocardial tissue samples were trimmed of fat and
homogenized for 1 mm in 4 vol of a 0.3 M sucrose solution
containing 10 mM imidazole (pH 7.0). The homogenate was
centrifuged at x 17,300g for 20 mm, and the pellet was sus-
pended in a standard buffer solution containing 60 mM KC1, 30
mM imidazole (pH 7.0), and m MgC12. This process of
homogenization, centrifugation, and resuspension was repeated
four times. The myofibrils were purified further by several
washings with standard buffer containing 1% Triton. The puri-
fied myofibrils were resuspended in standard buffer to a protein
concentration of 8 to 10 mgldl. The activity of creatine kinase
was determined and expressed per milligrams of protein.
Myofibrillar Ca ATPase was measured by a method previously
described [22].
Measurements of 45Ca uptake and total myocardial calcium
The uptake of 45Ca by the myocardium was determined by
the method of Fleckenstein et al [23]. After 4 days of 1-84 PTH
or vehicle administration, the animals received 20 Ci of 45Ca
per kg of body weight intraperitoneally at 6 A.M., of day 5 of the
study. Six hours later, the animals were sacrificed by decapita-
tion, blood was collected and a myocardial sample was ob-
tained; its wet weight was determined. The myocardial tissue
samples were dissolved in soluene x-lOO (Packard Instrument
Corp., Downers Grove, Illinois, USA); 1 ml of soluene was
used per 1 mg of wet weight tissue. 45Ca in blood and myocar-
dial samples was determined with a liquid scintillation counter
(Model L5 700, Beckman Instruments, Irvine. California,
USA). The myocardial uptake of 45Ca was expressed as a
percent uptake in I g of wet tissue relative to the counts in 100
ml of blood. Myocardial calcium content was determined in
another group of 1-84 PTH or vehicle-treated rats. After sacri-
fIce by decapitation, myocardial samples were obtained,
washed with saline, and wet weight was determined. The
samples were then dried in an oven for 24 hr at 105°C. Dry
weight was determined. The tissue samples were then ashed at
400°C for 4 to 6 hr. The ash was dissolved in 3 N nitric acid, and
calcium concentration was determined.
Evaluation of the effect of verapamil on the action of 1-84
PTH
We examined the effects of verapamil (Isoptene, Knoll AG,
Ludwigschagen, Germany) given intraperitoneally in a dose of
Z mg/kg body wt/day for 4 days to normal rats or to 1-84
PTH-treated animals on all parameters of myocardial
bioenergetics, 45Ca uptake, and total calcium content.
Measurement of blood pressure and cardiac output
Measurements of blood pressure and cardiac output were
performed after 4 and 10 days of 1-84 PTH or vehicle treatment.
On the last day of 1-84 PTH or vehicle administration, rats were
weighed and anesthetized with intraperitoneal injection of 40 to
50 mg of sodium pentobarbital/kg of body weight. Through an
incision on the ventral surface of the neck, both the left carotid
artery and jugular vein were cannulated with polyethylene
tubing (PE 50), Clay Adams, Parsippany, New Jersey, USA)
filled with a solution of sodium heparin (1000 IU/ml in 0.9%
saline). The tubings were led subcutaneously to emerge at the
base of the neck; they were then threaded through a thin wire
spring (PGE Scientific Corp., Rockville, Maryland, USA) 20 cm
long to protect the tubings. After surgery, the animals were
housed in individual cages. The tubings were passed through
the top of the cage to be connected to l-ml plastic syringes with
a 23-gauge hypodermic needle. Studies were done the following
day while rats were awake, unrestrained, and undisturbed.
Blood pressure was measured directly via the arterial cath-
eter which was connected to a pressure transducer (P-l0000B,
Narco Bio-Systems, Houston, Texas, USA) and strain gauge
amplifier and recorder (MK-III, Narco Bio-Systems). The mean
arterial pressure (MAP) was calculated as the sum of diastolic
blood pressure and one third of pulse pressure. Heart rate was
determined using the fluctuation of arterial blood pressure to
trigger a tachometer (Biotachometer, Coupler Type 7302,
Narco Bio-Systems).
Cardiac output was measured in duplicate by constant infu-
sion of indocyanine green. A baseline blood sample (0.5 ml) was
withdrawn before the injection of the dye, which was then
infused at a rate of 0.39 ml/min, of a solution containing 1.25
mg/dl.
Preliminary studies utilizing sequential measurements of the
concentration of the dye in the arterial blood showed that it
plateaus at 20 sec after initiation of the infusion. We, therefore,
obtained the blood samples for the dye concentration 20 sec
after the start of the infusion. A prototype transmission-reflec-
tion densitometer developed in our institution was used to
measure the concentration of the dye in the blood. The re-
producibility of the cardiac output was tested by using duplicate
measurements and the correlation between the two determina-
tions was excellent (r = 0.99, P < 0.01). The systemic vascular
resistance was calculated from MAP and cardiac index and
expressed in mm Hg/mllminlkg body wt.
Results
The dose of 1-84 PTH used in the present study did not cause
a significant rise in the blood levels of calcium, and the values
were 9.3 0.12 mg/dl in the control rats (N = 45), and 9.6
0.13 mg/dl in the PTH-treated animals (N = 45). On the other
hand, there was a modest but significant decrease (P < 0.01) in
the blood levels of inorganic phosphorus with the values being
7.7 1.18 mgldl in the control animals and 6.4 0.17 mgldl in
the PTH-treated rats. Similarly, the dose of 1-34 PTH did not
affect the blood levels of serum calcium but a modest and
significant (P <0.01) fall in blood levels of inorganic phospho-
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Table 1. Effects of PTH on the myocardial content of inorganic phosphorus, creatine phosphate, and adenine nucleotides
Myocardial content, jsmolesig protein
Pi CP ATP ADP AMP
Control PTH Control PTH Control PTH Control PTH Control PTH
22.0
21.0
18.0
19.0
17.1
21.0
14.2
19.0
13.0
14.0
12.0
17.0
32.0
27.0
26.0
31.5
29.7
31.0
5.0
10.0
8.5
3.2
7.5
10.0
17.0
19.0
18.5
16.2
15.0
20.8
6.5
8.5
3.5
5.4
6.5
12.5
5.1
4.0
3.2
4.2
3.8
3.9
1.3
1.8
2.0
2.2
1.3
1.8
1.1
1.3
0.9
0.8
1.3
1.4
0.5
0.8
0.4
0.9
1.0
0.6
Mean 19.6
0.8
14.9
1.1
29.6
1.0
7.4
1.1
17.8
0.9
7.2
1.3
4.0
0.2
1.7
0.1
1.1
0.1
0.7
0.1
P <0.05 <0.01 <0.01 <0.01 <0.01
Abbreviations: Pi, inorganic phosphorus; CP, creatine phosphate; ATP, adenosine triphosphate; ADP, adenosine diphosphate; AMP, adenosine
monophosphate.
Fig. 1. Effect of verapamil (LI) and verapamil plus PTH (LI) on the
myocardial content of inorganic phosphorus (Pi), ATP, and creatine
phosphate (CP). Control rats are represented by 0.
rus occurred in rats receiving 300 U/mi (8.4 0.30 vs. 6.6
0.15 mg/dl).
The effects of 1-84 PTH on myocardial contents of inorganic
phosphorus (Pi), adenine nucleotides, and creatine phosphate
(CP) are shown in Table 1. Treatment with 1-84 PTH produced
a significant decrease in the myocardial content of Pi, CP, and
all adenine nucieotides. These changes occurred in the face of
no change in myocardial content of creatine (53.7 2.44,
control, vs. 52.7 4.72, PTH, mg/g/protein) or DNA (2755
162, control, vs. 2785 225, PTH ig/g wet weight). The effects
of verapamil alone and of verapamil and 1-84 PTH are given in
Figure 1. Verapamil alone did not produce a significant change
in the myocardial content of Pi, CP, and adenine nucleotides.
The administration of verapamii to 1-84 PTH-treated rats pre-
vented the decrease in these parameters.
The respiratory control rates of heart mitochondria in both
the control animals (12.5 0.7) and the 1-84 PTH-treated rats
(9.8 0.8) were within the range of intact coupled
mitochondria. Administration of 1-84 PTH reduced oxygen
consumption by the mitochondria (Fig. 2), and there was a
significant (P < 0.01) difference in this parameter between the
control rats (103.5 4.5 nmoles 02/mg protein/mm) and those
treated with 1-84 PTH (77.6 3.6 nmole 02/mg protein/mm).
Administration of verapamil to 1-84 PTH-treated rats prevented
the fall in mitochondrial oxygen consumption (Fig. 2). The
ADP:0 ratio in the 1-84 PTH treated rats (3.7 0.06) was not
different from that of control animals (3.6 0.03).
The effects of 1-84 PTH, verapamil, and verapamil and 1-84
PTH on mitochondriai creatine phosphokinase (CPK), Mg
ATPase, and maximal oxygen consumption stimulated with
creatine are shown in Table 2. 1-84 PTH produced a significant
(P < 0.01) reduction in the activity of mitochondriai CPK and
Mg ATPase and a significant decrease (P < 0.01) in maximal
P1 ATP
C
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Fig. 2. Effect of PTH, verapamil and verapamil plus PTH on mitochon-
drial oxygen consumption. The asterisk denotes a significant difference
from other experimental conditions with the P < 0.01. Symbols are: 0,
control; LI, verapamil; , PTH; 0, verapamil and PTH.
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Table 2. Effects of PTH, verapamil, and verapamil and PTH on the activity of mitochondrial creatine phosphokinase and Mg ATPase and on
oxygen consumption at state 4 respiration stimulated with creatinea
CPK Mg ATPase Oxygen consumption at sta
+ creatine/ — creatine
te 4
lU/mg protein
Vera- Verapamil
nmoles Pi/mg protein/mm
Vera- Verapamil Vera- Verapamil
Control PTH pamil and PTH Control PTH pamil and PTH Control PTH pamil and PTH
2.1 1.8 2.0±0,1 325±20195±12310±8 278±21 1.4± 0.04 1.1 0.021.3±0.1 1.7±0,16
(14) (18) (11) (6) (10) (11) (7) (6) (13) (14) (11) (6)
P values
Control vs.
PTH <0.01 <0.01 <0.01
Control vs.
Verapamil NS NS NS
Control vs.
Verapamil
and PTH NS NS NS
a The number in parentheses denotes the number of rats studied; data are presented in mean SE.
Table 3. Effects of PTH, verapamil, and verapamil and PTH on the activity of myofibrillar creatine phosphokinase and Ca ATPasea
CPK Ca ATPase
nmoles P1/mg protein/mmlU/rng protein
Verapamil Verapamil
Control PTH Verapamil and PTH Control PTH Verapamil and PTH
1.7 0.1 0.4 0.03 1.0 0.07 1.2 0.12 217 19 63 7 96 7 116 8
(12) (10) (10) (8) (10) (6) (10) (8)
P values
Control vs. PTH <0.01 <0.01
Control vs.
Verapamil <0.01 <0.01
Control vs.
Verapamil
and PTH <0.01 <0.01
a The number in parentheses denotes the number of rats studied; data are presented in mean SE.
oxygen consumption at state 4 respiration stimulated with
creatine. These effects of 1-84 PTH were abolished by the
simultaneous administration of verapamil.
The effects of 1-84 PTH, verapamil, and verapamil and 1-84
PTH on the activity of myofibrillar CPK and Ca ATPase are
given in Table 3. 1-84 PTH produced a significant (P < 0.01)
decrease in the activity of myofibrillar CPK and Ca ATPase.
Verapamil alone produced similar effects as 1-84 PTH, but the
changes produced by 1-84 PTH were significantly (P < 0.01)
greater than those induced by verapamil. The simultaneous
treatment with verapamil and 1-84 PTH abolished the effects of
1-84 PTH. The activity of CPK and Ca ATPase under these
conditions was not different from those noticed with verapamil
alone,
The treatment with 1-84 PTH was associated with a signifi-
cantly (P < 0.01) higher uptake of 45Ca (53 1.5%) by the
myocardium than in control rats (41 1.3%) and with signifi-
cantly greater calcium content in the heart (49 3.8 vs. 16 1.4
g/g dry weight, Figure 3. The simultaneous administration of
verapamil to 1-84 PTH-treated rats prevented the enhanced
uptake of 45Ca and the increased content of calcium of the
heart.
The effects of inactivated 1-84 PTH and 200 or 300 U/day of
1-34 PTH on mitochondrial and myofibrillar function are given
in Table 4. Inactivation of 1-84 PTH abolished its effects on
mitochondrial oxygen consumption and on the activity of
creatine kinase of both mitochondrial and myofibrils. 1-34 PTH
(200 U/day) produced a significant (P < 0.01) decrease in the
activity of creatine kinase of mitochondria and myofibrils.
However, this dose (200 U/day) of 1-34 PTH did not affect
mitochondrial oxygen consumption, but the latter decreased
significantly (P < 0.01) when a higher dose (300 U/day) of 1-34
PTH was used.
The effects of 4 and 10 days of 1-84 PTH or vehicle treatment
on hemodynamic parameters are given in Table 5. There were
no significant differences in MAP, heart rate, cardiac index, or
total peripheral resistance between the two animal groups
treated for 4 days. After 10 days of therapy, both MAP (134
4.1 vs. 111 8.2mm Hg, P <0.05) and cardiac index (174 14
vs. 129 9 ml/minlkg, P < 0.025) were significantly lower in the
1-84 PTH-treated animals than in those receiving vehicle only.
Discussion
The results of the present study demonstrate that 4 days of
treatment with 1-84 PTH is associated with marked alterations
in myocardial energy metabolism as evidenced by reduction in
the concentration of inorganic phosphorus, adenine nucleotides
and creatine phosphate, impairment in mitochondrial oxygen
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I
Fig. 3. Effect of PTH and PTH plus verapamil on 45Ca uptake by the
myocardium and on myocardial calcium content. The asterisk denotes
a significant difference from other experimental conditions with P <
0.01. Symbols are: LI, control; U, PTH; LI, verapamil and PTH.
consumption and inhibition of mitochondrial as well as
myofibrillar creatine kinase isoenzymes. The demonstration
that the inactivation of 1-84 PTH abolished its effect on energy
production (mitochondrial oxygen consumption), shuttle and
utilization (activity of creatine kinase) is consistent with the
action that is related to the biologic activity of the hormone and
not to a contaminant of the hormone preparation. Further
support to this notion is provided by the finding that 1-34 PTH
which is a synthetic pure preparation of PTH also inhibited
mitochondrial oxygen consumption and the activity of mito-
chondrial and myofibrillar creatine phosphokinase. It is of
interest that a greater dose of 1-34 PTFI than of 1-84 PTH was
required to exert an effect of myocardial energetics. This is not
surprising since previous data also showed a greater effect of
1-84 PTH than 1-34 PTH on isolated heart cells [31. These data
further document that the heart is a target organ for PTH and
provide the basis for the understanding of the biochemical
events that may underlie the potential adverse effects of the
prolonged exposure to the hormone on the myocardium.
It should be mentioned that our measurements of myocardial
high energy compounds and inorganic phosphorus represent
total values and may not reflect changes in free levels of these
compounds which are the determinants of the true energy state
of the tissue. Free concentrations of inorganic phosphorus and
ADP could be determined accurately by the use of 31P nuclear
magnetic resonance, a method which has not been utilized in
our studies. The interpretation of our results is made with this
limitation in mind.
Fleckenstein [71 has shown that calcium overload in the
myocardium resulted in reduced ATP content. It is well known
that PTH increases calcium movement into, and the content of,
many mammalian cells [24—29], and it is possible that the
changes in the content of adenine nucleotides in our studies are
also due to enhanced entry of calcium into the myocardium.
The observations of our investigation are consistent with this
view. Indeed, the in vivo treatment with 1-84 PTFI enhanced
45Ca uptake by the myocardium and increased its calcium
content, and the simultaneous administration of verapamil
abolished both the PTH-induced calcium overload and the
effect of the hormone on adenine nucleotides.
It has been suggested that the decrease in myocardial ATP
content following calcium overload is most likely due to in-
creased ATP breakdown [71. An increase in ATP consumption
should be associated with a rise in inorganic phosphorus; the
latter, however, decreased during PTH administration, making
increased ATP breakdown an unlikely possibility. Two obser-
vations in our study suggest that decreased synthesis of ATP is
a more plausible mechanism for the reduced ATP content
during PTH administration. First, the fall in the concentration
of Pi reduced the availability of substrate for ATP synthesis;
and second, the inhibition of mitochondrial oxygen consump-
tion without a fall in ADP:Q ratio indicates reduced mitochon-
drial capacity to generate ATP.
The mechanisms responsible for the fall in the concentration
of myocardial Pi are not evident. Previous studies from our
laboratory [10] have shown that chronic phosphate depletion of
a 4-week duration is associated with marked hypophosphatemia
and a decrease in myocardial content of Pi. In the present study
with 1-84 PTH, the decrease in serum inorganic phosphorus
was modest and the fall in myocardial Pi occurred earlier
suggesting that other factors may be operative. Meyer and
Meyer [30] reported a decrease in total phosphorus content of
liver and skeletal muscle during PTH administration; they
suggested that this phenomenon was due to the loss of phos-
phorus in the urine. In our study, the simultaneous administra-
tion of verapamil prevented the fall in the myocardial content of
Pi induced by 1-84 PTH administration suggesting that this
effect of the hormone is related to its ability to enhance calcium
movement into the myocardium. It is interesting to speculate
that the excess calcium entering the cells may precipitate as
calcium phosphate compound reducing the concentration of
inorganic phosphorus. Indeed, Lehninger, Rossi, and
Greenawalt [31] have shown that calcium phosphate precipi-
tates in the mitochondria of liver cells during calcium loading.
This process requires energy and inorganic phosphorus. Electron-
opaque deposits of insoluble calcium salts have been noted in
kidney mitochondria exposed to excess PTH and calcium [32].
Synthesis of CP represents the transfer of energy generated
by oxidative phosphorylation by the mitochondria in the form
of ATP [33], and this transfer is facilitated by mitochondrial
creatine phosphokinase [14, 18, 33]. Thus, CP content depends
on the availability of creatine, ATP, and the activity of mito-
chondrial creatine phosphokinase. Our data showed that 1-84
PTH administration did not affect myocardial content of cre-
atine but reduced that of ATP and impaired the activity of
creatine phosphokinase. The changes in the latter two param-
eters are most likely responsible for the observed decrease in
CP content. The concept of the creatine phosphate energy
shuttle implies a disequilibrium in the creatine phosphokinase
reaction. Our data are compatible with this notion as evidenced
by two findings. First, there was a marked fall in creatine
phosphate in the face of no change in total creatine suggesting
an increase in free creatine, which is based on the calculation
that total creatine equals creatine phosphate plus free creatine.
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Table 4. Effect of inactivated 1-84 PTH and 200 and 300 U/day of 1-34 PTH on mitochondnal and myofibnllar functiona
Inactivated 1-34 PTH
Control (7) 1-84 PTH (6) 200 U/day (6)
1-34 PTH
300 U/day (6)
Mitochondrial function
Respiratory control ratio 11.8 0.8 13.4 0.7 10.1 0.6 9.7 0.9
ADP:0 2.81 0.02 2.88 0.07 2.78 0.06 2.84 0.04
Oxygen consumption
nmoles/02/mgprotein/min 134.6 0.1 141.7 8.4 142,8 6.2 114.7 3,9b
Creatine phosphokinase
lU/mg protein 1.94 0.1 2.27 0.2 1.28 0,1b
Myofibrillar function
Creatine phosphokinase
lU/mg protein 1.54 0.1 1.80 0.2 1.28 0,09b
a The number in parentheses denotes the number of rats studied; data are presented in mean SE.
b P < 0.01 vs. control,
Table 5. Effect of 4 and 10 days of PTH or vehicle treatment on hemodynamic parametersa
Weight MAP HR CO CI TPR
g mm Hg beats/mm mi/mm mI/mm/kg mm Hg/mi/mm/kg
4-day treatment
Vehicle (5) 244 16 135 4.5 361 29 41 2.8 172 20 0.8 0.11
PTH (5) 221 19 121 9.9 309 32 48 7.5 230 47 0.7 0.25
P NS NS NS NS NS NS
10-day treatment
Vehicle (7) 290 17 134 4.1 360 17 50 3.4 174 14 0.8 0.07
PTH (6) 258 12 Ill 8.2 353 19 33 2.4 129 9 0.8 0.09
P NS <0.05 NS <0.01 <0.025 NS
Abbreviations: MAP, mean arterial pressure; HR, heart rate; CU, cardiac output; Cl, cardiac index; TPR, total peripheral resistance.
a Data are presented as mean sE; the number in parentheses denotes the number of animals.
Second, despite these changes in creatine phosphate and crc-
atine, the ATP/ADP ratio was not affected.
We have shown previously that the in vitro incubation of
myocardial mitochondna with 1-84 PTH in the presence of
calcium inhibited mitochondrial respiration and oxidative phos-
phorylation [34]. Our present results extend these observations
and demonstrate that the in vivo administration of 1-84 or 1-34
PTH produced similar effects. Also, similar in vivo actions of
PTH on renal cortex mitochondria have been observed [35, 361.
Because the in vitro effect of PTH required the presence of both
excess hormone and calcium around the mitochondria [34] and
because the in vivo effects occurred after several hours [35, 36]
or days (present study) of hormone treatment, one may assume
that PTH or one of its fragments must enter the myocardial cell
and approach the mitochondria before its effects become evi-
dent. Such an event has been demonstrated in the kidney by
Nordiquest and Palmeiri [371. They showed that PTH enters the
cells of the renal proximal tubule and localizes in the
mitochondria.
The observation that the simultaneous administration of
verapamil prevented the 1-84 PTH-induced inhibition of mito-
chondrial functions assigns an important role for the 1-84
PTH—mediated enhanced entry of calcium in this process. This
is consistent with the in vitro findings that both excess PTH and
calcium are needed for the inhibition of mitochondrial respira-
tion and oxidative phosphorylation [34]. It is of interest that the
studies in vitro showed that PTH in the presence of calcium
reduced ADP:0 ratio [34] while the in vivo administration of
PTH did not exert a similar effect. This difference may be due
to the higher concentrations of PTH and calcium used in the in
vitro studies. Since in the in vivo studies, 1-84 PTH inhibited
both oxygen consumption and Mg ATPase activity without a
change in ADP:0 ratio, one may assume a proportional inhibi-
tion of these two mitochondrial functions.
Myofibrillar creatine phosphokinase is a key enzyme in the
energy shuttle from its source at the mitochondria to its
utilization sites at the myofibrils [33]. This enzyme facilitates
the transfer of energy from creatine phosphate to ADP to
generate ATP. This transfer of energy at the myofibrils is
critical for the contraction and relaxation of the muscle. The
inhibition of the activity of creatine phosphokinase by 1-84 or
1-34 PTH would impair this process and result in decreased
energy utilization and disturbed function. Available data indi-
cate that myofibrillar Ca ATPase is involved in initiation of
muscle contraction [38]; therefore, the inhibition of the activity
of this enzyme by 1-84 PTH would interfere with myofibrillar
function.
Our data provide evidence that 1-84 and 1-34 PTH adversely
affects energy production, transfer, and utilization by the
myocardium. These observations are similar to those reported
in chronic phosphate depletion [10]. In the phosphate-depleted
animals, there was a decrease in the concentration of myocar-
dial inorganic phosphorus and this change played a major role in
the alterations of the myocardial bioenergetics [10]. It is pos-
sible that the effects of PTH observed in the present study are
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mediated, at least partially, by the decrease in myocardial
content of inorganic phosphorus.
The alteration in the bioenergetics of the myocardium after 4
days of 1-84 or 1-34 PTH administration did not affect cardiac
output or blood pressure but both were significantly lower than
in control animals after 10 days of 1-84 PTH treatment. These
observations suggest that a prolonged exposure to PTH is
required before the changes in the myocardial bioenergetics are
reflected by disturbances in function.
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